CoChat

Nonconventional glucagon and GLP-1 receptor agonist and antagonist interplay at the GLP-1 receptor revealed in high-throughput FRET assays for cAMP

Open access
Chepurny, Oleg G., Matsoukas, Minos-Timotheos, Liapakis, George, Leech, Colin A., Milliken, Brandon T., Doyle, Robert P., Holz, George G. · 2019 · Journal of Biological Chemistry
Cited by 41

The DOI matches its Crossref record; 18 of the 18 references it cites were found in a registry or an index.

Abstract

G protein–coupled receptors (GPCRs) for glucagon (GluR) and glucagon-like peptide-1 (GLP-1R) are normally considered to be highly selective for glucagon and GLP-1, respectively. However, glucagon secreted from pancreatic α-cells may accumulate at high concentrations to exert promiscuous effects at the β-cell GLP-1R, as may occur in the volume-restricted microenvironment of the islets of Langerhans. Furthermore, systemic administration of GluR or GLP-1R agonists and antagonists at high doses may lead to off-target effects at other receptors. Here, we used molecular modeling to evaluate data derived from FRET assays that detect cAMP as a read-out for GluR and GLP-1R activation. This analysis established that glucagon is a nonconventional GLP-1R agonist, an effect inhibited by the GLP-1R orthosteric antagonist exendin(9–39) (Ex(9–39)). The GluR allosteric inhibitors LY2409021 and MK 0893 antagonized glucagon and GLP-1 action at the GLP-1R, whereas des-His 1 -[Glu 9 ]glucagon antagonized glucagon action at the GluR, while having minimal inhibitory action versus glucagon or GLP-1 at the GLP-1R. When testing Ex(9–39) in combination with des-His 1 -[Glu 9 ]glucagon in INS-1 832/13 cells, we validated a dual agonist action of glucagon at the GluR and GLP-1R. Hybrid peptide GGP817 containing glucagon fused to a fragment of peptide YY (PYY) acted as a triagonist at the GluR, GLP-1R, and neuropeptide Y2 receptor (NPY2R). Collectively, these findings provide a new triagonist strategy with which to target the GluR, GLP-1R, and NPY2R. They also provide an impetus to reevaluate prior studies in which GluR and GLP-1R agonists and antagonists were assumed not to exert promiscuous actions at other GPCRs.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1074/jbc.ra118.005682

Cites

18 of 18 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 18 references

Research works printed but not linked: 61

  1. Skow, 2016, Diabetes and obesity treatment based on dual incretin receptor activation: 'twincretins', Diabetes Obes. Metab, 18, 847, 10.1111/dom.12685 · DOI · Paper page
  2. Brandt, 2018, Gut hormone polyagonists for the treatment of type 2 diabetes, Peptides, 100, 190, 10.1016/j.peptides.2017.12.021 · DOI · Paper page
  3. Liapakis, 2017, Family B G protein-coupled receptors and their ligands: from structure to function, Curr. Med. Chem, 24, 3323, 10.2174/0929867324666170303162416 · doi:10.2174/0929867324666170303162416
  4. Parker, 2008, Neuropeptide Y Y2 receptor in health and disease, Br. J. Pharmacol, 153, 420, 10.1038/sj.bjp.0707445 · DOI
  5. Scott, 2018, Problem or solution: the strange story of glucagon, Peptides, 100, 36, 10.1016/j.peptides.2017.11.013 · DOI · Paper page
  6. Holz, 2003, Glucagon-like peptide-1 synthetic analogs: new therapeutic agents for use in the treatment of diabetes mellitus, Curr. Med. Chem, 10, 2471, 10.2174/0929867033456648 · DOI · Paper page
  7. Habib, 2013, Co-localisation and secretion of glucagon-like peptide 1 and peptide YY from primary cultured human L cells, Diabetologia, 56, 1413, 10.1007/s00125-013-2887-z · DOI · Paper page
  8. Wren, 2007, Gut hormones and appetite control, Gastroenterology, 132, 2116, 10.1053/j.gastro.2007.03.048 · DOI · Paper page
  9. Thorens, 1993, Cloning and functional expression of the human islet GLP-1 receptor. Demonstration that exendin-4 is an agonist and exendin-(9–39) an antagonist of the receptor, Diabetes, 42, 1678, 10.2337/diab.42.11.1678 · DOI · Paper page
  10. Runge, 2008, Crystal structure of the ligand-bound glucagon-like peptide-1 receptor extracellular domain, J. Biol. Chem, 283, 11340, 10.1074/jbc.M708740200 · DOI · Paper page
  11. Unson, 1987, Synthetic peptide antagonists of glucagon, Proc. Natl. Acad. Sci. U.S.A, 84, 4083, 10.1073/pnas.84.12.4083 · DOI
  12. Kazda, 2016, Evaluation of efficacy and safety of the glucagon receptor antagonist LY2409021 in patients with type 2 diabetes: 12- and 24-week phase 2 studies, Diabetes Care, 39, 1241, 10.2337/dc15-1643 · DOI · Paper page
  13. Xiong, 2012, Discovery of a novel glucagon receptor antagonist N-[(4-{(1S)-1-[3-(3,5-dichlorophenyl)-5-(6-methoxynaphthalen-2-yl)-1H-pyrazol-1-yl]ethyl}phenyl)carbonyl]-β-alanine (MK-0893) for the treatment of type II diabetes, J. Med. Chem, 55, 6137, 10.1021/jm300579z · DOI · Paper page
  14. Jazayeri, 2016, Extra-helical binding site of a glucagon receptor antagonist, Nature, 533, 274, 10.1038/nature17414 · DOI · Paper page
  15. Chepurny, 2018, Chimeric peptide EP45 as a dual agonist at GLP-1 and NPY2R receptors, Sci. Rep, 8
  16. Klarenbeek, 2015, Fourth-generation Epac-based FRET sensors for cAMP feature exceptional brightness, photostability and dynamic range: characterization of dedicated sensors for FLIM, for ratiometry and with high affinity, PLoS ONE, 10, 10.1371/journal.pone.0122513 · DOI · Paper page
  17. Dumont, 2000, BIIE0246, a potent and highly selective non-peptide neuropeptide Y Y2 receptor antagonist, Br. J. Pharmacol, 129, 1075, 10.1038/sj.bjp.0703162 · DOI
  18. Jelinek, 1993, Expression cloning and signaling properties of the rat glucagon receptor, Science, 259, 1614, 10.1126/science.8384375 · DOI · Paper page
  19. Gremlich, 1995, Cloning, functional expression, and chromosomal localization of the human pancreatic islet glucose-dependent insulinotropic polypeptide receptor, Diabetes, 44, 1202, 10.2337/diab.44.10.1202 · DOI · Paper page
  20. Cooper, 1997, An endogenous A2B adenosine receptor coupled to cyclic AMP generation in human embryonic kidney (HEK 293) cells, Br. J. Pharmacol, 122, 546, 10.1038/sj.bjp.0701401 · DOI
  21. Hohmeier, 2000, Isolation of INS-1-derived cell lines with robust ATP-sensitive K+ channel-dependent and -independent glucose-stimulated insulin secretion, Diabetes, 49, 424, 10.2337/diabetes.49.3.424 · DOI · Paper page
  22. Zhang, 2017, Structure of the full-length glucagon class B G-protein-coupled receptor, Nature, 546, 259, 10.1038/nature22363 · DOI · Paper page
  23. Wootten, 2013, Polar transmembrane interactions drive formation of ligand-specific and signal pathway-biased family B G protein-coupled receptor conformations, Proc. Natl. Acad. Sci. U.S.A, 110, 5211, 10.1073/pnas.1221585110 · DOI · Paper page
  24. Underwood, 2010, Crystal structure of glucagon-like peptide-1 in complex with the extracellular domain of the glucagon-like peptide-1 receptor, J. Biol. Chem, 285, 723, 10.1074/jbc.M109.033829 · DOI · Paper page
  25. Zhang, 2017, Cryo-EM structure of the activated GLP-1 receptor in complex with a G protein, Nature, 546, 248, 10.1038/nature22394 · DOI · Paper page
  26. Zhang, 2018, Structure of the glucagon receptor in complex with a glucagon analogue, Nature, 553, 106, 10.1038/nature25153 · DOI
  27. Chabenne, 2014, A glucagon analog chemically stabilized for immediate treatment of life-threatening hypoglycemia, Mol. Metabol, 3, 293, 10.1016/j.molmet.2014.01.006 · DOI
  28. Liang, 2018, Phase-plate cryo-EM structure of a biased agonist-bound human GLP-1 receptor-Gs complex, Nature, 555, 121, 10.1038/nature25773 · DOI · Paper page
  29. Xiao, 2000, Characterization of glucagon-like peptide-1 receptor-binding determinants, J. Mol. Endocrinol, 25, 321, 10.1677/jme.0.0250321 · DOI · Paper page
  30. Dong, 2008, Insights into the structural basis of endogenous agonist activation of family B G protein-coupled receptors, Mol. Endocrinol, 22, 1489, 10.1210/me.2008-0025 · DOI
  31. Moens, 1998, Dual glucagon recognition by pancreatic β-cells via glucagon and glucagon-like peptide-1 receptors, Diabetes, 47, 66, 10.2337/diab.47.1.66 · DOI · Paper page
  32. Nie, 2000, Regulation of pancreatic PC1 and PC2 associated with increased glucagon-like peptide 1 in diabetic rats, J. Clin. Invest, 105, 955, 10.1172/JCI7456 · DOI · Paper page
  33. Whalley, 2011, Processing of proglucagon to GLP-1 in pancreatic alpha-cells: is this a paracrine mechanism enabling GLP-1 to act on beta-cells?, J. Endocrinol, 211, 99, 10.1530/JOE-11-0094 · DOI · Paper page
  34. Marchetti, 2012, A local glucagon-like peptide 1 (GLP-1) system in human pancreatic islets, Diabetologia, 55, 3262, 10.1007/s00125-012-2716-9 · DOI · Paper page
  35. Donath, 2013, GLP-1 effects on islets: hormonal, neuronal, or paracrine?, Diabetes Care, 36, S145, 10.2337/dcS13-2015 · DOI · Paper page
  36. O'Malley, 2014, Progressive change of intra-islet GLP-1 production during diabetes development, Diabetes Metab. Res. Rev, 30, 661, 10.1002/dmrr.2534 · DOI · Paper page
  37. Svendsen, 2018, Insulin secretion depends on intra-islet glucagon signaling, Cell Rep, 25, 1127, 10.1016/j.celrep.2018.10.018 · DOI · Paper page
  38. Kawai, 1995, Evidence that glucagon stimulates insulin secretion through its own receptor in rats, Diabetologia, 38, 274, 10.1007/BF00400630 · DOI
  39. Serre, 1998, Exendin-(9–39) is an inverse agonist of the murine glucagon-like peptide-1 receptor: implications for basal intracellular cyclic adenosine 3′,5′-monophosphate levels and beta-cell glucose competence, Endocrinology, 139, 4448, 10.1210/endo.139.11.6295 · DOI · Paper page
  40. Rose, 1995, Cloning and functional expression of a cDNA encoding a human type 2 neuropeptide Y receptor, J. Biol. Chem, 270, 22661, 10.1074/jbc.270.39.22661 · DOI · Paper page
  41. Holz, 1992, Signal transduction crosstalk in the endocrine system: pancreatic beta-cells and the glucose competence concept, Trends Biochem. Sci, 17, 388, 10.1016/0968-0004(92)90006-U · DOI
  42. Holz, 1993, Pancreatic beta-cells are rendered glucose-competent by the insulinotropic hormone glucagon-like peptide-1(7–37), Nature, 361, 362, 10.1038/361362a0 · DOI · Paper page
  43. Chepurny, 2002, Exendin-4 as a stimulator of rat insulin I gene promoter activity via bZIP/CRE interactions sensitive to serine/threonine protein kinase inhibitor Ro 31-8220, Endocrinology, 143, 2303, 10.1210/endo.143.6.8870 · doi:10.1210/endo.143.6.8870 · Paper page
  44. Holz, 2004, New insights concerning the glucose-dependent insulin secretagogue action of glucagon-like peptide-1 in pancreatic beta-cells, Horm. Metab. Res, 36, 787, 10.1055/s-2004-826165 · DOI · Paper page
  45. Holz, 2005, Diabetes outfoxed by GLP-1?, Sci. STKE, 2005, pe2, 10.1126/stke.2682005pe2 · DOI · Paper page
  46. Leech, 2011, Molecular physiology of glucagon-like peptide-1 insulin secretagogue action in pancreatic beta cells, Prog. Biophys. Mol. Biol, 107, 236, 10.1016/j.pbiomolbio.2011.07.005 · DOI · Paper page
  47. Calabria, 2012, GLP-1 receptor antagonist exendin-(9–39) elevates fasting blood glucose levels in congenital hyperinsulinism owing to inactivating mutations in the ATP-sensitive K+ channel, Diabetes, 61, 2585, 10.2337/db12-0166 · DOI · Paper page
  48. Sathananthan, 2013, Direct effects of exendin-(9,39) and GLP-1-(9–36)amide on insulin action, beta-cell function, and glucose metabolism in nondiabetic subjects, Diabetes, 62, 2752, 10.2337/db13-0140 · DOI · Paper page
  49. Chambers, 2017, The role of pancreatic preproglucagon in glucose homeostasis in mice, Cell Metab, 25, 927, 10.1016/j.cmet.2017.02.008 · DOI · Paper page
  50. Karageorgos, 2018, Current understanding of the structure and function of family B GPCRs to design novel drugs, Hormones (Athens), 17, 45, 10.1007/s42000-018-0009-5 · DOI
  51. Engel, 2011, Efficacy and tolerability of MK-0893, a glucagon receptor antagonist (GRA), in patients with type 2 diabetes (T2DM), Diabetes, 60, A85
  52. Kjaergaard, 2019, PYY(3–36) and exendin-4 reduce food intake and activate neuronal circuits in a synergistic manner in mice, Neuropeptides, 73, 89, 10.1016/j.npep.2018.11.004 · DOI
  53. Gromada, 1995, Stimulation of cloned human glucagon-like peptide 1 receptor expressed in HEK 293 cells induces cAMP-dependent activation of calcium-induced calcium release, FEBS Lett, 373, 182, 10.1016/0014-5793(95)01070-U · DOI · Paper page
  54. Jiang, 2001, Glucagon receptor activates extracellular signal-regulated protein kinase 1/2 via cAMP-dependent protein kinase, Proc. Natl. Acad. Sci. U.S.A, 98, 10102, 10.1073/pnas.131200398 · DOI · Paper page
  55. Kim, 2005, A novel mechanism for the suppression of a voltage-gated potassium channel by glucose-dependent insulinotropic polypeptide: protein kinase A-dependent endocytosis, J. Biol. Chem, 280, 28692, 10.1074/jbc.M504913200 · DOI · Paper page
  56. Chepurny, 2007, A novel cyclic adenosine monophosphate responsive luciferase reporter incorporating a nonpalindromic cyclic adenosine monophosphate response element provides optimal performance for use in G protein coupled receptor drug discovery efforts, J. Biomol. Screen, 12, 740, 10.1177/1087057107301856 · DOI
  57. Allen, 2006, Subcellular dynamics of protein kinase A activity visualized by FRET-based reporters, Biochem. Biophys. Res. Commun, 348, 716, 10.1016/j.bbrc.2006.07.136 · DOI · Paper page
  58. Chepurny, 2009, Enhanced Rap1 activation and insulin secretagogue properties of an acetoxymethyl ester of an Epac-selective cyclic AMP analog in rat INS-1 cells: studies with 8-pCPT-2′-O-Me-cAMP-AM, J. Biol. Chem, 284, 10728, 10.1074/jbc.M900166200 · DOI · Paper page
  59. Schwede, 2015, Rp-cAMPS prodrugs reveal the cAMP dependence of first-phase glucose-stimulated insulin secretion, Mol. Endocrinol, 29, 988, 10.1210/me.2014-1330 · DOI
  60. Koebel, 2016, S...O and S...N sulfur bonding interactions in protein-ligand complexes: empirical considerations and scoring function, J. Chem. Inf. Model, 56, 2298, 10.1021/acs.jcim.6b00236 · DOI
  61. Trott, 2010, AutoDock Vina: improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreading, J. Comput. Chem, 31, 455, 10.1002/jcc.21334 · DOI · Paper page

Cited by

See all 41

Metadata

Authors
Chepurny, O. G., Matsoukas, M.-T., Liapakis, G., Leech, C. A., Milliken, B. T., Doyle, R. P., & Holz, G. G.
Venue
Journal of Biological Chemistry
Publisher
Elsevier BV
Published
2019-03
Volume
294
Issue
10
Pages
3514-3531
ISSN
0021-9258 (ISSN-L)
OpenAlex
W2909281962
Cited by
41
References
18
FWCI
1.72
Type
journal article
Language
en
Update notices
erratum (2019-05-31)
Open access
hybrid
Licence
Funders
HHS | NIH | National Institute of Diabetes and Digestive and Kidney Diseases (R01-DK069575)

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Nonconventional glucagon and GLP-1 receptor agonist and antagonist interplay at the GLP-1 receptor revealed in high-throughput FRET assays for cAMP. https://app.cochat.ai/papers/10.1074/jbc.ra118.005682
The paper
Chepurny, O. G., Matsoukas, M.-T., Liapakis, G., Leech, C. A., Milliken, B. T., Doyle, R. P., & Holz, G. G. (2019). Nonconventional glucagon and GLP-1 receptor agonist and antagonist interplay at the GLP-1 receptor revealed in high-throughput FRET assays for cAMP. Journal of Biological Chemistry. https://doi.org/10.1074/jbc.ra118.005682

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.